KIORA PHARMACEUTICALS, INC. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability
KIORA PHARMACEUTICALS, INC. (KPRX) had Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability of $1.21 million as of 2016-09-30, per its 10-Q filed 2016-11-01.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less) › Business Combination, Recognized Liability Assumed, Liability
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability · last filed 2016-11-01
- 2016-09-30: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability $1.21M.
- 2016-06-30: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability -$1.21M.
- 2016-03-31: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability -$1.21M.
| Period end | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability |
|---|---|
| 2016-09-30 | $1.21M 10-Q · filed 2016-11-01 |
| 2016-06-30 | -$1.21M 10-Q · filed 2016-08-10 |
| 2016-03-31 | -$1.21M 10-Q · filed 2016-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |